15 2019 INTEGRATED SUMMARY REPORT Revenue Growth Across Therapeutic Areas ($ millions, percent growth) ENDOCRINOLOGY ONCOLOGY IMMUNOLOGY NEUROSCIENCE OTHER $12,814.4 $4,614.4 $1,793.3 $1,722.9 $1,374.5 +10% +8% +57% -5% -47% Revenue in Endocrinology increased 10% primarily driven by growth of Trulicity, Basaglar and Jardiance. Oncology revenue increased 8% due to Verzenio launch in the U.S. Taltz drove the 57% revenue increase in Immunology. Neuroscience experienced a 5% decrease due to lower volume for Strattera as a result of loss of patent protection, offset in part by the launch of Emgality. Other Pharmaceutical revenue decreased 47% driven by lower volumes for Cialis, due to patent losses. Product Revenue Growth Revenue Per Employee ($ in millions represent growth in revenue excluding foreign currency impact) ($ thousands, percent growth) TRULCITY $964.5 $650 $664 $575 +13% +2% TALTZ $443.1 $490 $510 +13% +3% +4% VERZENIO $323.8 BASAGLAR $320.9 JARDIANCE $301.6 OLUMIANT $239.7 EMGALITY $157.6 2015 2016 2017 2018 2019 Seven products – Trulicity, Taltz, Verzenio, Basaglar, Jardiance, In 2019, revenue per employee increased 2% to $664,000, primarily Olumiant and Emgality – together generated revenue growth due to higher revenue driven by volume growth from Trulicity and of $2.8 billion excluding the impact of foreign currency, other new products. driven primarily by volume increases.